Abstracts

Search by keyword or author name.

Showing 14 abstracts.

Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to < 6 years: Results from IMPAACT P1093

Conference

IAS 2018

Study

P1093

Authors

R Singh, C Alvero, T Fenton, K George, S Popson, E Townley, R Hazra, C Brothers, C Vavro, A Buchanan, A Wiznia, IMPAACT P1093 team, T Ruel, E Acosta

Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093)

Conference

IAS 2023

Study

P1093, P1093

Authors

Robert Nixon, Robert A. Smith, Geoffrey S. Gottlieb, Theodore D. Ruel, Andrew A. Wiznia, Lisa M. Frenkel, IMPAACT P1093 Team, Ceejay L. Boyce, Marley D. Bishop, Sheila M. Styrchak, Kevin Knowles, Cindy Vavro, Rohan Hazra, Ellen Townley

Emergence of Resistance in HIV-1 Integrase (IN) Following Dolutegravir (DTG) Treatment in 6 to 18 Year Old Participants Enrolled in the P1093 Study

Conference

IAS 2018

Study

P1093

Authors

Cindy Vavro, Ted Ruel, Andrew Wiznia, Carmelita Alvero, Stephanie Popson, Terry Fenton, Rohan Hazra, Ellen Townley, Ann Buchanan, Paul Palumbo

Evolution of HIV-1 Integrase Following Selection of R263K with Further Dolutegravir Treatment; A Case Report from the P1093 study.

Conference

IAS 2015

Study

P1093

Authors

Cindy Vavro, Paul Palumbo, Andrew Wiznia, Carmelita Alvero, Bobbie Graham, Terry Fenton, Rohan Hazra, Ellen O’Gara, Ann M Buchanan, Joe Horton, Rolando M Viani

Dolutegravir and Growth in Pediatric Populations With HIV-1: IMPAACT P1093 and IMPAACT 2019

Conference

CROI 2024

Study

P1093, IMPAACT 2019

Authors

Lauren Ziemba, Theodore Ruel, Patricia M. Flynn, Helena Rabie, Andrew Wiznia, Michael McKenna, Zrinka Lulic, Ann M. Buchanan, Cynthia Brothers, Lionel Tan, Marcia Wang, Sean Brummel

Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-Week Results from IMPAACT P1093

Study

P1093

Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093)

Conference

IAS 2023

Authors

Ceejay Boyce

PK and 4-week outcomes of dolutegravir dispersible tablets in HIV-infected children

Conference

CROI 2019

Study

P1093

Authors

R Singh, C Alvero, K George, S Popson, M Bartlett, A Buchanan, C Brothers, L Koech, T Vhembo, R Hazra, E Townley, A Wiznia, P1093 team, T Ruel, E Acosta

IMPAACT 1093: Dolutegravir in 6-12 Year Old HIV Infected Children: 48-Week Results

Conference

CROI 2016

Study

P1093

Authors

Andrew Wiznia, Carmelita Alvero, Terry Fenton, Kathleen George, Ellen Townley, Rohan Hazra, Barb Heckman, Annie Buchannan, Cindy Vavro, Rolando Viani on behalf of the P1093 study team

Pharmacokinetics, Safety, and Efficacy of Dolutegravir (DTG; S/GSK1349572) in HIV-1 Infected Adolescents: Preliminary analysis from IMPAACT 1093

Conference

XIX International AIDS Conference

Study

P1093